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Abstract
In the past, we proposed to develop a heterologous recombinant BCG prime-recombinant modified vaccinia virus Ankara
(MVA) boost dual pediatric vaccine platform against transmission of breast milk HIV-1 and Mycobacterium tuberculosis (Mtb).
In this study, we assembled an E. coli-mycobacterial shuttle plasmid pJH222.HIVACAT expressing HIV-1 clade A immunogen
HIVA. This shuttle vector employs an antibiotic resistance-free mechanism based on Operator-Repressor Titration (ORT)
system for plasmid selection and maintenance in E. coli and lysine complementation in mycobacteria. This shuttle plasmid
was electroporated into parental lysine auxotroph (safer) strain of BCG to generate vaccine BCG.HIVACAT. All procedures
complied with Good Laboratory Practices (GLPs). We demonstrated that the episomal plasmid pJH222.HIVACAT was stable in
vivo over a 20-week period, and genetically and phenotypically characterized the BCG.HIVACAT vaccine strain. The
BCG.HIVACAT vaccine in combination with MVA.HIVA induced HIV-1- and Mtb-specific interferon c-producing T-cell
responses in newborn and adult BALB/c mice. On the other hand, when adult mice were primed with BCG.HIVACAT and
boosted with MVA.HIVA.85A, HIV-1-specific CD8+ T-cells producing IFN-c, TNF-a, IL-2 and CD107a were induced. To assess
the biosafety profile of BCG.HIVACAT-MVA.HIVA regimen, body mass loss of newborn mice was monitored regularly
throughout the vaccination experiment and no difference was observed between the vaccinated and naı̈ve groups of
animals. Thus, we demonstrated T-cell immunogenicity of a novel, safer, GLP-compatible BCG-vectored vaccine using
prototype immunogen HIVA. Second generation immunogens derived from HIV-1 as well as other major pediatric
pathogens can be constructed in a similar fashion to prime protective responses soon after birth.
Citation: Saubi N, Mbewe-Mvula A, Gea-Mallorqui E, Rosario M, Gatell JM, et al. (2012) Pre-Clinical Development of BCG.HIVACAT, an Antibiotic-Free Selection
Strain, for HIV-TB Pediatric Vaccine Vectored by Lysine Auxotroph of BCG. PLoS ONE 7(8): e42559. doi:10.1371/journal.pone.0042559
Editor: Clive M. Gray, University of Cape Town, South Africa
Received March 13, 2012; Accepted July 9, 2012; Published August 21, 2012
Copyright:  2012 Saubi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The sources of funding that have supported the work are: EDCTP (Grant: CT.2006.33111.002; http://www.edctp.org); MRC, United Kingdom (Grant:
G1001757; http://www.mrc.ac.uk/); and HIVACAT: AIDS Vaccine Research Project (http://www.hivacat.org/en). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jjoseph@clinic.ub.es
¤ Current address: Medical Microbiology and Immunology, Li Ka Shing Institute of Virology, Edmonton, Alberta, Canada
Introduction
According to the last UNAIDS World AIDS Day Report 2011,
at the end of 2010, an estimated 34 million people were living with
HIV worldwide and 2.7 million individuals became newly infected
with the virus in 2010. The number of people dying of AIDS-
related causes was 1.8 million in 2010, and it is estimated that
more than 16 million children have been orphaned by AIDS. Sub-
Saharan Africa accounted for 70% of new HIV infections in 2010,
and even though it is encouraging that 6.6 million people are
currently receiving treatment in resource-poor settings, ensuring
universal access to antiretrovirals still represents an enormous
challenge [1]. Without access to drugs, rates of HIV-1 Mother-to-
child transmission (MTCT) are 15–30% in non breastfeeding
populations. Breastfeeding by an infected mother adds an
additional 5–20% risk leading to an overall transmission rate of
20–45% as shown in some African and Asian settings [2].
Development of effective and safe neonatal and/or adult vaccines
is the best solution to prevent infection or reduce the severity of
HIV-related diseases. Infection with Mycobacterium tuberculosis (Mtb)
kills about 2 million people each year and goes hand-in-hand with
HIV-1. Mycobacterium bovis bacillus Calmette–Guérin (BCG) is the
only licensed vaccine and protects significantly against childhood
and milliary tuberculosis. Globally, 80% of children are vaccinated
with BCG, the majority of them at birth. Thus, the development of
a combined vaccine, which would protect neonates against
tuberculosis and MTCT of HIV-1 through breastfeeding, is a
logical effort in the fight against these two major global killers.
Only two candidate vaccines designed to protect against breast
milk HIV transmission have been studied in human infants (HIV-
1 gp120 recombinant subunit and live-attenuated recombinant
canarypox ALVAC vaccines) [3–5]. Therefore, there is an urgent
need for a neonatal immunogen that generates HIV-specific
immunity more rapidly. Recombinant BCG (rBCG) has been
developed as a candidate neonatal vaccine vector against pertussis
[6], measles [7], respiratory syncytial virus (RSV) [8] and breast
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milk HIV transmission [9,10]. BCG as a vaccine vector has a
number of attractive features. BCG has a proven record of safety
as a vaccine against tuberculosis from its use in over two billion
individuals [11]. However, BCG has now been questioned for
safety, especially in HIV-endemic regions where both HIV and
TB are highly endemic. Currently, HIV infection in infants is now
a full contraindication to BCG vaccination [12]. Nevertheless, the
BCG Working Group of the International Union against
Tuberculosis and Lung recommended that current universal
BCG immunisation of infants continue in countries highly
endemic for TB until they have all programmes in place for
implementing selective deferral of HIV-exposed infants [13]. BCG
infects and colonizes macrophages and dendritic cells, where it can
survive and replicate for a long period of time. Through its
persistence and potent adjuvantation by its cell wall components, it
can induce long-lasting humoral and cellular immune responses.
BCG can be given at or any time after birth, and is not affected by
maternal antibodies [14,15]. Manufacturing of BCG-based
vaccines is inexpensive. Finally, BCG is one of the most heat-
stable vaccines in current use [16].
There is strong evidence in favour of a role for HIV-1 specific
T-cell responses in the control of HIV-1 replication [17,18]. One
promising approach for T-cell induction is Mycobacterium bovis BCG
as a bacterial live recombinant vaccine vehicle. Specific humoral
and cellular immune responses against HIV-1 have been detected
after immunization of mice with rBCG expressing HIV-1 antigens
[19–21]. For a number of years, we have been working on rBCG
based HIV-1 vaccine development with the aim to induce
protective cell-mediated responses. Our starting platform was
based on a heterologous rBCG prime and recombinant modified
vaccinia virus Ankara (MVA) boost regimen delivering a common
immunogen called HIVA, which is derived from consensus Gag
protein of HIV-1 clade A, prevalent in Central and Eastern Africa,
and a string of CD8+ T-cell epitopes [22]. BCG.HIVA222 carrying
an episomal plasmid expressing HIVA was shown to be stable and
to induce durable, oligofunctional HIV-1-specific CD4+ and CD8+
T-cell responses in BALB/c mice. Furthermore, when the
BCG.HIVA222 vaccine was used in a prime-boost regimen with
heterologous vectors, HIV-1-specific responses provided protec-
tion against surrogate virus challenge expressing HIVA, and was
also as efficient in protecting against aerosol challenge with Mtb as
the BCG 1173 P2 vaccine Pasteur strain. The BCG.HIVA222
vaccine candidate was vectored by a lysine auxotroph of BCG
Pasteur strain that carried an E. coli-mycobacterial shuttle plasmid
pJH222.HIVA with a lysine A complementing gene and a weak
promoter to drive HIVA gene expression [10]. This design
increases the plasmid stability in vivo and prevents heterologous
gene expression disruption by genetic rearrangement [23]. We also
evaluated the influence of BALB/c mice age and immunization
routes on induction of HIV-1 and Mtb-specific immune responses.
Administration of BCG.HIVA222 to newborn mice was safe and
primed HIV-1-specific immune responses boosted by subsequent
MVA.HIVA administration [24]. Also, MVA.HIVA.85A, a dual
AIDS and tuberculosis vaccine, was designed to boost both the
Mtb and HIV-1-specific immune responses primed by
BCG.HIVA222 [25].
In this study, we constructed a novel HIVA-expressing E. coli-
mycobacterial shuttle plasmid pJH222.HIVACAT by using an
antibiotic-free plasmid selection system based on Operator-
Repressor Titration (ORT) system in E. coli and lysine comple-
mentation in mycobacteria. This plasmid DNA was electroporated
into parental lysine auxotroph of BCG to generate vaccine
BCG.HIVACAT. The genetic and phenotypic characterization of
antibiotic markerless BCG.HIVACAT strain was performed. The
presence of HIVA gene sequence and protein expression by the
recombinant mycobacterium were confirmed, its safety was
evaluated by monitoring the body mass gain and the induction
of HIV-1 and Mtb-specific immune responses was demonstrated in
both newborn and adult BALB/c mice after BCG.HIVACAT
prime and MVA.HIVA or MVA.HIVA.85A boost. The BCG.HI-
VACAT strain was developed in GLP-compatible conditions,
properly characterized, stable in vivo, induced specific HIV-1 and
Mtb immune responses in newborn and adult mice and was well
tolerated in newborn mice. In addition, the compatibility with
GLP requirements is relevant for progressing this novel vaccine
into clinical evaluation.
Results
Construction of the BCG.HIVACAT vaccine strain
HIVA immunogen consists of consensus HIV-1 clade A Gag
p24/p17 domains coupled to a string of CD8+ T-cell epitopes and
monoclonal antibody (mAb) tag Pk [22]. The HIVA gene was
synthesized utilizing humanized GC-rich codons, which are
similar to those used by mycobacteria [26,27]. To facilitate the
pre-clinical development of candidate vaccines, the HIVA
immunogen contains an immunodominant H-2Dd-murine re-
stricted epitope P18-I10 [28]. The HIVA open-reading frame was
fused at its 59 end to nucleotides coding for the 19-kDa lipoprotein
signal sequence, which facilitates the antigen secretion and fusion
of foreign antigens to mycobacterial surface lipoproteins, enhanc-
ing the foreign protein immunogenicity [29]. The chimeric 19-
kDa signal sequence-HIVA gene was expressed from E. coli-
mycobacterial shuttle plasmid pJH222 under the control of the
Mtb a-antigen promoter (Figure 1A). Plasmid DNA pJH222 is a
replicative (multicopy, extrachromosomal) vector that contains a
DNA cassette encoding kanamycin resistance (Tn903-derived aph
gene), an E. coli origin of replication (oriE) and a mycobacterial
plasmid DNA origin of replication (oriM). It also contains the wild-
type lysine A-complementing gene for the vector maintenance
(lysA5) in the BCG auxotroph [10]. The kanamycin resistance gene
was removed from pJH222.HIVA vector by using the Operator-
Repressor Titration (ORT) system developed by Cobra Biologics
(UK). Such system enables the selection and maintenance of
plasmids that are free from expressed selectable marker genes and
require only the short, non-expressed lac operator for selection and
maintenance [30]. The principle Escherichia coli ORT strain,
DH1lacdapD [31], has been used to produce several important
DNA vaccine candidates such as the HIV-1 vaccine pTHr.HIVA
[32]. In this work the kanamycin resistance gene was replaced with
a lac operator sequence and the resulting plasmid, pJH222.HI-
VACAT was transformed into the E.coli DH1lacdapD strain
(Figure 1A). When the non-expressed lac operator sequence was
inserted into multicopy plasmid and introduced into the cell, the
binding of the repressor protein to the plasmid-borne operator
derepresses the chromosomal operator and allows dapD expression
and cell growth [32]. The recombinant pJH222.HIVA containing
the ORT selection system, here designated as pJH222.HIVACAT,
was transformed into lysine auxotroph of BCG host strain Pasteur
DlysA5::res [33]. The selection of positive BCG.HIVACAT
colonies was made by growing the rBCG cells on Middlebrook
agar 7H10 medium with no supplementation of lysine. Expression
of the full-size chimeric 19-kDa signal sequence-HIVA protein was
confirmed by immunodot of whole transformed mycobacterial cell
lysates using anti-Pk mAb. As shown in Figure 1B, the highest level
of HIVA protein expression was detected after blotting the BCG
culture from clone number 10 and was selected for further
molecular characterization, immunogenicity and safety testing in
Bivalent Pediatric Vaccine for HIV-TB
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mice. On the other hand, the BCG.HIVACAT clone10 culture was
preserved by using the seed-lot system. A Master Seed stock, and
derivative Working Stock, which we used also as a Vaccine stock
was prepared. Growth of the transformed mycobacteria and the in
vivo stability of pJH222.HIVACAT episomal plasmid were estab-
lished by the recovery of BCG.HIVACAT colonies from the spleens
of BALB/c mice 20 weeks after immunization. Six out of six
recovered rBCG colonies were positive for HIVA DNA coding
sequence by PCR (Figure 1C).
Genetic characterization of the BCG.HIVACAT
In order to confirm that our recombinant BCG.HIVACAT
vaccine strain corresponds to M. bovis BCG strain, we used the
GenoType MTBC assay based on a commercially available DNA
strip assay (Hain Lifescience GmbH, Nehren, Germany) intended
for the differentiation of members of the Mycobacterium tuberculosis
complex (MTBC) and identification of M. bovis BCG. This assay is
based on gyrB DNA sequence polymorphisms and the RD1
deletion of M. bovis BCG. Specific oligonucleotides targeting these
polymorphisms are immobilized on membrane strips. Amplicons
derived from a multiplex PCR react with these probes during
hybridization. Each strip has a total of 13 reaction zones.
Amplification bands 4–13 include specific probes for each of the
tuberculosis complex species. The combination of several hybrid-
ization patterns enables to identify the different species of MTBC.
Interpretation of the GenoType MTBC hybridization patterns
was performed on the basis of the description included in the test.
The hybridization patterns were all unequivocal and could easily
be allocated to species. Sample results were then compared with
the classical differentiation results. We tested four samples
corresponding to commercial BCG Connaught, BCG.HIVA222,
BCG.HIVACAT (clone10) and BCG Pasteur strains. As we show in
Figure 2A, all four strains presented the same hybridization
pattern corresponding to M. bovis BCG, detecting the bands 4, 7,
9, 10 and 13 belonging specifically to BCG hybridization pattern.
Distribution of BCG to several countries for worldwide
application started around 1924 and it was preserved by in vitro
subculture passaging until 1960s. Since then the Pasteur strain has
been freeze-dried, keeping the form of the primary seed lot. The in
vitro evolution of BCG has resulted in a number of BCG substrains
Figure 1. Construction of the BCG.HIVACAT vaccine strain. (A) A synthetic GC-rich HIVA gene was fused to the region encoding the 19-kDa
lipoprotein signal sequence and inserted into the episomal pJH222 E. coli-mycobacterium shuttle plasmid. This plasmid contains kanamycin
resistance (aph) and complementing lysA genes and an E. coli origin of replication (oriE). In addition, pJH222 contained the mycobacterial origin of
replication (oriM). The BALB/c mouse T-cell and MAb Pk epitopes used in this work are depicted. P a-Ag, M. tuberculosis a-antigen promoter; PHSP60,
heat shock protein 60 gene promoter. The aph gene was removed by SpeI digestion and the lacO sequence was inserted and transformed into E. coli
DH1lacdapD strain. (B) Immunodot of BCG.HIVACAT lysates. Dot 1: BCG wild type (negative control); Dot 2, 3, 4 and 5: clone 3, clone 7, clone 9 and
clone 10 of BCG.HIVACAT; Dot 6: BCG.HIVA222 (positive control). HIVA peptide was detected using the anti-Pk MAb followed by horseradish
peroxidase-Goat-anti-Mouse and enhanced chemiluminescence (ECL) detection. (C) In vivo plasmid stability of BCG.HIVACAT harboring
pJH222.HIVACAT. Mice were injected s.c. with 105 cfu of BCG.HIVACAT and boosted i.m. with 106 pfu of MVA.HIVA, spleens were homogenized 20
weeks after BCG inoculation and the recovered rBCG colonies were tested for the presence of the HIVA DNA coding sequence by PCR. Lanes 1 to 6:
Six rBCG colonies were recovered in the non-lysine supplemented plate; lane 7: Molecular weight marker; lane 8: Plasmid DNA positive control; lane 9:
Distilled water (negative control).
doi:10.1371/journal.pone.0042559.g001
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that are heterogenic [34–37]. Genetic identification techniques
have been used to differentiate diverse BCG substrains: i) the gene
probe based on IS986; ii) restriction fragments patterns; iii) whole-
genome DNA microarray and iv) multiplex PCR. Using this last
method it was reported that the deletion of RD1 occurred in 23 of
23 BCG strains tested. In order to confirm that our BCG.HIVA-
CAT vaccine strain correspond to BCG Pasteur substrain, we have
used the method described by Bedwell et al. [38] based on
multiplex PCR system targeting SenX3-RegX3 system and the
BCG deletion regions including RD1, 2, 8, 14 and 16. Using this
method, the BCG vaccine substrains studied could be differenti-
ated into seven fingerprints and all BCG substrains were
confirmed. We tested the following samples: BCG.HIVACAT
strain (clone10) Pasteur substrain and commercial BCG Danish
1331 strain. Both BCG substrains evaluated gave a 196 bp
product with primers ET1-3, indicating deletion of the RD1
region. In addition in BCG Pasteur (BCG.HIVACAT) the RD8
and RD16 were present and gave a product of 472 and 401 bp
respectively. The primers for the SenX3-RegX3 region gave a
product of 276 bp in BCG Pasteur. The PCR fingerprints of BCG
Pasteur and BCG Danish substrains (Figure 2B) were consistent
with previously published results on genetic information of BCG
substrains [38]. As shown in Figure 2B, the yield of the PCR was
higher when the single primer pairs were used, instead of multiplex
format.
For the molecular characterization of pJH222.HIVACAT
plasmid DNA, enzymatic restriction and PCR analysis were
performed. The plasmid DNA was isolated from the Master seed
and Working stock of BCG.HIVACAT strain and was character-
ized. The enzymatic restriction pattern obtained did not show any
difference with the predicted enzymatic pattern of the plasmid
DNA sequence. HpaI (lanes 2 and 8): band of 6857 bp; KpnI
(lanes 3 and 9): bands of 3758, 2117 and 982 bp; SpeI (lanes 4 and
10): band of 6815 bp; HindIII (lanes 5 and 11): bands of 5228 and
1629 bp (Figure 2C). On the other hand, the PCR analysis using
specific primers for the HIVA DNA coding sequence was
Figure 2. Genetic characterization of the BCG.HIVACAT. GenoType MTBC assay and Multiplex PCR assay. (A) The BCG.HIVACAT strain
identification results representative of all of the patterns obtained with the GenoType MTBC assay. The positions of the oligonucleotides, the marker
line and the BCG hybridization pattern are shown on the right. The specificity and targeted genes of the lines are as follows: 1, conjugate control; 2,
amplification control (23S rRNA); 3, MTBC specific (23S rRNA); 4 to 12, discriminative for the MTBC species (gyrB); 13, M. bovis BCG (RD1). The samples
analyzed were: Strip 1: BCG Connaught; Strip 2: BCG.HIVACAT; Strip 3: BCG.HIVA222; Strip 4: BCG wild type. All four strains presented the same
hybridization pattern corresponding to M. bovis BCG. (B) The BCG.HIVACAT Pasteur substrain identification by multiplex PCR assay. Lane 1 and 12:
molecular weight marker; lane 2: negative control; lane 3, 6–11: BCG.HIVACAT(clone10); lane 4: BCG Danish strain (using 1 ml of template); lane 5: BCG
Danish strain (using 4 ml template); The samples were analyzed by multiplex primer assay or single primer pair assay. Lane 2–5: multiplex primers;
lane 6: ET1-3 primers; lane 7: RD2 primers; lane 8: RD8 primers; lane 9: RD14 primers; lane 10: RD16 primers; lane 11: C3–C5 primers. (C) Enzymatic
restriction analysis of pJH222.HIVACAT plasmid DNA extracted from both the Master Seed (MS, lanes 1–5) and the Working Stock (WS, lanes 7–11) of
BCG.HIVACAT cultures. Lane 1 and lane 7: uncut plasmid; lane 2 and lane 8: HpaI digestion; lane 3 and 9: KpnI digestion; lane 4 and 10: digestion with
SpeI; lane 5 and 11: digestion with HindIII; lane 6 and 12: Molecular Weight Marker (1 kb Plus, Invitrogen). (D) PCR analysis of HIVA DNA coding
sequence using as template the cultures of BCG.HIVACAT Master Seed (lane 1), and Working Stock (lane 2), Molecular Weight Marker (lane 3), positive
control plasmid DNA pJH222.HIVA (lane 4).
doi:10.1371/journal.pone.0042559.g002
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performed using the BCG liquid culture from BCG.HIVACAT
Master seed and Working stock as template. A band of 1776 bp
corresponding to HIVA DNA fragment was detected (Figure 2D).
Phenotypic characterization of the BCG.HIVACAT
To prevent the plasmid instability in vivo and in vitro and the
genetic rearrangement by mycobacteria, different approaches
should be considered: i) the use of expression vectors containing
small HIV-1 DNA coding sequences, ii) DNA fragments lacking
glycosylation sites; iii) the use of weak promoters; iv) the use of
BCG auxotrophic strains (containing the complementing gene in
the expression vectors); v) the use of inducible promoters; vi) codon
optimization of the recombinant gene; vii) the choice of expression
vector backbone and viii) antigen secretion to enhance the
immunogenicity and to prevent foreign proteins from becoming
toxic to BCG. We have demonstrated that the use of weak
promoters (Mycobacteria spp. a-antigen promoter) and BCG lysine
auxotrophs complemented with a lysine gene do, in fact, prevent
the disruption of gene expression caused by genetic rearrange-
ments [23]. In this study, we have used a BCG strain auxotroph
for lysine complemented with a lysine gene and antibiotic-free
plasmid selection system (no kanamycin resistance). We assessed
the phenotype stability of lysine auxotrophy, lysine complemen-
tation and kanamycin resistance of BCG.HIVACAT strain.
Initially, the BCG lysine auxotroph strain was plated out on
lysine supplemented and non supplemented agar. Such strain
failed to grow on non lysine supplemented agar plates and no
colonies were observed (Figure 3A). However, growth was
observed on agar plates supplemented with lysine (Figure 3B).
As expected, complementation of BCG.HIVACAT strain with
lysine gene provided on the multicopy plasmid pJH222.HIVACAT
abolished the requirement for exogenous lysine (Figure 3C). On
the other hand, when BCG.HIVACAT strain was plated out on
agar plates containing kanamycin, no colonies were observed
(Figure 3D), confirming the lack of kanamycin resistance in our
construct.
BCG.HIVACAT prime and MVA.HIVA boost regimen
elicited HIV-1-specific CD8+ and PPD-specific T-cell
responses in mice
We have demonstrated in previous studies in BALB/c mice that
BCG.HIVA222 can both prime novel and boost preexisting
MVA.HIVA elicited HIV-1 specific CD4+ and CD8+ T-cells
immune responses of high quality upon antigenic reexposure. In
this study, we have evaluated the specific HIV-1 T-cell immune
responses in adult and newborn BALB/c mice after immunization
with BCG.HIVACAT prime and MVA.HIVA or MVA.HIVA.85A
boost. The immunogenicity readout was focused on the P18-I10
epitope, an immunodominant CTL epitope derived from HIV-1
Env and H-2Dd murine restricted, which was fused to HIVA
immunogen to evaluate the immunogenity in mice (Figure 1A).
On day 0, adult mice were immunized with rBCG with the
episomal plasmid, and on week 12 the animals received a booster
dose with MVA.HIVA.85A (Figure 4A). On week 14, the mice
were sacrificed and the functional quality of the elicited CD8+ T-
cells to produce IFN-c, TNF-a, IL-2 and to degranulate (surface
expression of CD107a) in response to P18-I10 peptide stimulation
was measured by intracellular cytokine staining (ICS) (Figure 4B).
At the higher dose, BCG.HIVACAT alone and in combination
with MVA.HIVA.85A induced HIV-1-specific CD8+ T-cells,
producing IFN-c, TNF-a, and CD107a. For TNF-a, and
CD107a, there was a trend of increased responses following
MVA.HIVA.85A boost if these were primed by the BCG.HIVA-
CAT vaccine. In another animal experiment, on day 0, adult and
newborn mice were immunized with rBCG, and on week 14 the
animals received a booster dose with MVA.HIVA (Figure 4C). We
have observed in adult mice that BCG.HIVACAT prime and
MVA.HIVA boost induced higher frequencies of P18-I10 epitope
specific CD8+ splenocytes producing IFN-c than newborn and
naı̈ve mice (p,0.05) (Figure 4D). These data are in concordance
with our previously published results in which the proportions of
HIV-1 specific T-cells producing IFN-c and TNF-a were higher in
adult mice compared with newborn mice [24]. Moreover, the
magnitude of the bifunctional response was also lower in newborn
mice than in adult mice.
BCG.HIVACAT elicited PPD-specific responses in mice. The
BCG-specific immune responses were assessed following the
vaccine regimen consisting of BCG.HIVACAT prime and
MVA.HIVA boost as described in Figure 4C. The capacity of
splenocytes from vaccinated mice to secrete IFN-c was tested by
ELISPOT assays. The splenocytes secreted IFN-c after overnight
stimulation with the PPD antigen. The frequencies of specific cells
secreting IFN-c was higher in adult mice than in newborn and
naı̈ve mice (p,0.05) (Figure 4E).
BCG.HIVACAT prime and MVA.HIVA boost was well
tolerated in newborn mice
Ten newborn mice (7-days-old) per group were either immu-
nized or left unimmunized with 26106 colony forming units (cfu)
of BCG wild type, BCG.HIVA222 or BCG.HIVACAT via
subcutaneous route and subsequently given a booster dose of
106 plaque forming units (pfu) of MVA.HIVA via intramuscular as
described in Figure 5A. As shown in Figure 5B, the body mass was
weekly monitored and recorded. All vaccine combinations were
analyzed, to depict any possible adverse events due to vaccination
and monitored by body mass loss. For rigorous safety assessment,
Figure 3. Phenotypic characterization of the BCG.HIVACAT. We
assessed the phenotype of lysine auxotrophy, lysine complementation
and kanamycin resistance of BCG.HIVACAT strain. (A) BCG lysine
auxotroph strain plated on non-lysine supplemented 7H10; (B) BCG
lysine auxotroph strain plated on lysine supplemented 7H10; (C)
BCG.HIVACAT plated on 7H10 without lysine and kanamycin supple-
mentation; (D) BCG.HIVACAT plated on 7H10 without lysine supple-
mentation and with kanamycin.
doi:10.1371/journal.pone.0042559.g003
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the dose inoculated to newborn mice was 10- fold higher, as
advised by the European Pharmacopoeia for the safety testing of
live vaccines, in comparison with the most usual inoculation dose
in adult mice [39]. Importantly, no statistically significant
difference was observed between the vaccinated mice groups
and the naı̈ve mice group at specific time points, corresponding to
Figure 4. Induction of HIV-1- and Mtb-specific T-cells responses by the BCG.HIVACAT prime - MVA.HIVA boost regimen. (A) Adult mice
(7-weeks-old) immunized with either 104 or 105 cfu of BCG.HIVACAT alone (subcutaneously), 106 pfu of MVA.HIVA.85A alone (intramuscularly), or 104
or 105 cfu of BCG.HIVACAT as a prime and boosted with 106 pfu of MVA.HIVA.85A (left to right). Mice were sacrificed 2 weeks later for T-cell analysis.
(B) Analysis of IFN-c, TNF-a, CD107a and IL-2 vaccine elicited HIV-1-specific CD8+ T-cell responses. The frequencies of cells producing cytokine are
shown. Data are presented as group medians as well as individual animal responses (n = 5). (C) Adult and newborn mice (7-days-old) were either left
unimmunized or immunized with 26106 cfu of BCG.HIVACAT (intradermal and subcutaneous route respectively) and subsequently given a booster
dose of 106 pfu of MVA.HIVA (intramuscularly) at 14 weeks post BCG immunization, and sacrificed 3 weeks later. (D) Analysis of IFN-c vaccine elicited
HIV-1-specific CD8+ T-cell responses. The frequencies of cells producing cytokine are shown. Data are presented as group medians as well as
individual animal responses (n = 4). (E) PPD-specific T-cell responses elicited by BCG.HIVACAT. Immune responses to BCG were assessed in an ex vivo
IFN-c ELISPOT assay using PPD as the antigen. The median spot-forming units (SFU) per 106 splenocytes for each group of mice (n = 4) as well as
individual animal responses is shown. * = p,0.05.
doi:10.1371/journal.pone.0042559.g004
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BCG inoculation, 2 months after BCG inoculation, pre-MVA
boosting and three weeks post MVA-boosting. On the other hand,
the body mass profile was similar in all mice groups and similar to
mice provider company standard body mass curve (www.Harlan.
com). Furthermore, between week 0 and week 14, the body mass
monitored in all vaccinated mice groups was found between the
mean 6 2 standard deviations (SD) body mass curve in naı̈ve mice
(Figure 5B). It is also important to mention that no mice died
during the trial, no local adverse events, and no associated
systemic reactions were observed.
Discussion
Despite the progress made on prevention of mother-to-child
HIV-1 transmission, the development of a safe, effective and
affordable vaccine against HIV-1 and TB at the earliest time after
birth to prevent breast milk HIV-1 transmission and childhood
tuberculosis is still a great challenge. In this study, i) we have
constructed the E. coli-mycobacterial shuttle vector to express the
HIVA immunogen by using an antibiotic-free plasmid selection
system; ii) the genetic and phenotypic characterization of the
recombinant lysine auxotroph of BCG.HIVACAT strain was
performed; iii) the HIVA protein expression was confirmed; iv)
the specific HIV-1 and Mtb-specific immune responses after adult
and newborn mice immunization with BCG.HIVACAT prime and
MVA.HIVA or MVA.HIVA.85A boost was evaluated and v) the
biosafety profile after newborn mice immunization was monitored.
The BCG.HIVACAT strain was developed in GLP-compatible
conditions, preserved by the seed-lot system and was genetically
and phenotypically characterized. The E. coli-mycobacterial
shuttle vector that contains the antibiotic-free plasmid selection
system was stable in vivo for at least 20 weeks after mice
immunization and was used to construct a markerless BCG.HI-
VACAT vaccine suitable for Good Manufacturing Practice.
Overall, we have demonstrated that BCG.HIVACAT prime-
MVA.HIVA boost regimen was well tolerated in newborn mice
and induced HIV-1 and Mtb-specific immune responses in adult
and newborn mice. Thus, this strategy might be worthy to pursue
and for joining the global efforts to develop novel BCG vector-
based vaccines for controlling TB and HIV/AIDS.
Even though, it has been described that antibiotics and
antibiotic resistance genes have been traditionally used for the
Figure 5. BCG.HIVACAT prime and MVA.HIVA boost safety in newborn mice. (A) Newborn mice were either left unimmunized or immunized
with 26106 cfu of BCG wild type, BCG:HIVA222 or BCG.HIVACAT by subcutaneous route and subsequently given a booster dose of 106 pfu of
MVA.HIVA at week 14. (B) The body weight was weekly recorded, and the mean for each group of mice is shown (n = 10). Data from naive mice are
presented as mean 6 2 SEM (n = 6); At specific time points the weight differences between vaccinated and naı̈ve mice group were analyzed by
ANOVA test (arrowheads).
doi:10.1371/journal.pone.0042559.g005
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selection and maintenance of recombinant plasmids in hosts such
as Escherichia coli, their use has been considered unacceptable for
clinical trials and product licensing. Several approaches have been
pursued to replace antibiotics as selective markers for plasmid
stability in bacteria, including plasmids harboring gene comple-
mentation of a host auxotrophy. In our study, we have used the
Operator-Repressor Titration system (ORT) reported by Cranen-
burgh et al. [31], that utilizes E. coli DH1lacdapD strain that enables
plasmid selection and maintenance that is free from antibiotics and
selectable marker genes. This is achieved by using only the lac
operator (lacO) sequence as a selectable element. On the other
hand the E. coli-mycobacterial expression vector contains the
lysine A complementing gene of lysine auxotroph of BCG.
Classically, identification of the individual species that comprise
Mycobacterium tuberculosis complex (MTBC), M. tuberculosis, M. bovis,
M. bovis BCG, M. africanum, M. microti, and M. canetti, has been
based on phenotypic characteristics and biochemical tests [40].
These tests are slow, need sufficient bacterial growth, are time
consuming and the interpretation is subjective and could provide
identification errors. To overcome these problems, the use of more
reliable methods based on molecular biology techniques is
necessary. Several DNA-based techniques have been described
for the differentiation of members of the MTBC. SpoIigotyping
and other molecular methods have been useful tools for rapid
species differentiation [41–43]. The RD1 deletion identification by
PCR was found to be useful for M. bovis BCG identification [44].
Niemann et al. [45] have established a PCR-restriction fragment
length polymorphism assay that allows rapid differentiation of M.
bovis subsp. bovis, M. bovis subsp. caprae, and M. microti. The same
group in 2003 evaluated a commercially available DNA strip assay
(Genotype MTBC) for differentiation of clinical MTBC isolates
[46]. In this work, we have used also the GenoType MTBC assay
to identify our recombinant M. bovis BCG vaccine candidate
strain. The hybridization pattern obtained was unequivocal and
corresponded to M. bovis BCG.
The conventional methods for the identification of Mycobacterium
bovis BCG (BCG) vaccines, based on microscopic examination,
biochemical tests and morphological appearance, provided only
limited substrain differentiation and no specificity for BCG. The
best way to identify different BCG substrains is by using molecular
methods and genomic approaches. Differences between BCG
substrains have been detected by i) TB genome sequencing [47]; ii)
DNA microarray technology [48]; iii) PCR methods [49] and
multiplex PCR identity test for BCG vaccines described by
Bedwell et al. [38]. The PCR fingerprints produced from DNA
samples were concordant with predictions based on genetic
information on BCG substrains. The capability of this multiplex
PCR to discriminate between BCG substrains was tested using
commercial preparations and was proven also to be suitable for
identification of BCG in clinical samples as well as vaccines.
Specific identification of BCG isolates from a variety of clinical
situations including immunosuppresed children and adults under-
going therapy for bladder cancer has been performed by using the
multiplex PCR based on RD1 deletion region. In this work, we
have used the multiplex PCR assay to identify our BCG.HIVACAT
vaccine candidate. Resultant fingerprints after multiplex PCR
assay of our BCG vaccine Pasteur substrain, were consistent with
the PCR pattern of BCG Pasteur.
Our group and others have shown in murine and non-human
primates studies, that rBCG elicited cell-mediated responses
against HIV-1 and simian immunodeficiency virus antigens
[20,24,50–52]. However, a small proportion of these animal
studies used rBCG strains in heterologous prime-boost regimens.
Ami et al. [53] have demonstrated that macaques vaccinated with
rBCG expressing SIV gag and boosted with replication defective
poxvirus-SIV gag, elicited effective protective immunity against
mucosal challenge with SHIV KS661c. There is data showing that
rBCG is a good priming vector in heterologous prime-boost
vaccination regimens with attenuated virus or recombinant
proteins to enhance specific T-cell responses [10,54,55]. In
tuberculosis vaccine human trials, McShane et al. [56], have
demonstrated that vaccination with MVA expressing Ag85A
boosts pre-existing antimycobacterial immune responses induced
either by environmental mycobacteria or BCG vaccination.
Hovav et al. [57] have shown that priming with recombinant
Mycobacterium smegmatis expressing HIV-1 gp120 protein induced a
cellular immune response that is biased towards memory CD8+ T-
cells and that can expand dramatically on reexposure to an HIV-1
envelope antigen. We have previously shown in BALB/c mice that
the inclusion of BCG.HIVA222 in a heterologous prime-boost
regimen can prime and increase the HIV-1 specific T-cell immune
responses elicited by MVA.HIVA and MVA.HIVA.Ag85A
[10,24,25,58]. In addition, BCG.HIVA prime and MVA.HIVA
boost-elicited HIV-1 specific CD8+ T-cells exhibited effector
functions such as production of IFN-c and TNF-a. These HIV-1-
specific T-cell responses were higher in adult than in newborn
mice. The prime-boost regimen consistently enhanced and
improved the frequency, quality and durability of the generated
HIV-1 specific responses in adult and newborn mice. This
improvement was observed by the detection of the highest
bifunctional HIVA-specific T-cell responses and higher specific
cytolytic activity in the mice that received BCG.HIVA versus
BCG wild type. These data are consistent with the specific HIV-1
specific immune responses detected in this study after newborn
and adult mice immunization with BCG.HIVACAT prime and
MVA.HIVA boost, observing higher HIV-1 specific T-cell
responses in adult than in newborn mice. In addition, in adult
mice, BCG.HIVACAT primed and enhanced the MVA.HI-
VA.85A-elicited HIV-1-specific CD8+ T-cell responses. There
are few reports in the literature describing the safety and
immunogenicity of rBCG expressing HIV-1 antigens in neonatal
mice and neonatal non-human primates. Ranganathan et al. [9]
have evaluated the immunogenicity in neonatal mice of three
different recombinant attenuated Mtb strains expressing an HIV-1
envelope and showed that single dose immunization in neonatal
mice with DlysA DsecA2 Mtb strain expressing HIV-1 Env rapidly
generated HIV-1 and Mtb- specific T-cell immune responses. In
the present study, we showed in newborn mice that BCG.HIVA-
CAT prime and MVA.HIVA boost increased the frequencies of
specific CD8+ T-cells producing IFN-c. We observed in newborn
mice a lower level of HIV-1 specific T-cell immune responses
compared with adult mice. Rosario et al. [59] have assessed the
immunogenicity of the BCG.HIVA222 prime and MVA.HIVA
boost regimen in newborn rhesus macaques and made similar
observation. On the other hand, we suggest that additional
experiments should be performed in newborn mice inoculating the
rBCG expressing HIV-1 antigens by different routes and different
doses, because the route and dose of neonatal vaccination may
provide different levels of immune activation, which may affect the
efficacy of the vaccine.
Here, the vaccination with BCG.HIVACAT strain induced
BCG-specific responses in adult and newborn mice. Studies in
neonatal mice have indicated that immune responses at birth are
often biased towards the Th2 type and defective in the Th1 type,
the central defense mechanism against intracellular pathogens.
However, it has been described that BCG vaccination at birth
induces a potent Th1-type immune response in humans and in
mice [60,61].
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The challenge for neonatal vaccinology is thus to develop, and
promote at a global level, vaccines that could be safely
administered soon after birth and would be effective after one or
two early doses. According to our knowledge, no reports have
been published about safety of antibiotic-free marker recombinant
BCG based HIV-1 vaccine in neonatal mice. Rosario et al. [59]
have demonstrated that BCG.HIVA401 followed by two doses of
MVA.HIVA in rhesus macaques was safe, not associated with
systemic reactions and the local adverse events detected were
considered to be consistent with a predicted response to the BCG
vaccine administration, similar to that observed in human
neonates. In the present study, we have demonstrated in neonatal
mice (7-days-old) by the rate of body mass that BCG.HIVACAT
prime and MVA.HIVA boost regimen was well tolerated.
In conclusion, we constructed and characterized a novel, safer,
GLP-compatible BCG-vectored vaccine using prototype immu-
nogen HIVA and tested the safety and immunogenicity of
BCG.HIVACATand MVA.HIVA in newborn and adult mice
using the prime-boost regimen. BCG expressing a second
generation immunogen HIVconsv better addressing the HIV-1
variability and escape [62] is under construction. The same
strategy can be easily used for other major pediatric pathogens.
Materials and Methods
Construction of BCG.HIVACAT strain by using an
antibiotic-free plasmid selection system and expressing
HIV-1 clade A immunogen
Parental E. coli-mycobacterial shuttle vector, plasmid pJH222,
was kindly provided by W. R. Jacobs Jr., B.R. Bloom, and T. Hsu.
The coding sequence of the HIVA gene (derived from consensus
HIV-1 clade A Gag protein, an immunogen derived from an HIV-
1 strain prevalent in central and eastern Africa, and a string of
CD8+ T-cell epitopes) was fused to the M. tuberculosis nucleotides
coding for the 19-kDa lipoprotein signal sequence by PCR, and
the chimeric gene was cloned into the pJH222 as a HindIII-
HindIII fragment under the control of the M. tuberculosis a-antigen
promoter by using standard recombinant-DNA techniques.
Plasmid DNA pJH222 is a replicative (multicopy, extrachromo-
somal) vector that contains a DNA cassette encoding kanamycin
resistance (Tn903-derived aph gene), an E. coli origin of replication
(oriE), and a mycobacterial plasmid DNA origin of replication
(oriM). It contains also the wild-type lysine A-complementing gene
for the vector maintenance (lysA5) in the BCG lysine auxotroph
[4]. The aminoglycoside phosphotransferase gene (aph), confer-
ring kanamycin resistance, was removed from pJH222.HIVA
plasmid by using the Operator-Repressor Titration (ORT) system,
developed by Cobra Biologics, Oxford, UK [30]. Following aph
gene excision by plasmid DNA SpeI digestion, a tighter-binding
20 bp variant of the lacO sequence (generated by annealing
complementary oligonucleotides) was ligated and transformed into
E. coli DH1lacdapD strain.
Mycobacterial strains and culture
The pJH222.HIVA plasmid DNA without kanamycin resis-
tance gene, here designated as pJH222.HIVACAT plasmid, was
transformed by electroporation in a lysine auxotroph of BCG,
kindly provided by W.R. Jacobs Jr., B.R. Bloom, and T. Hsu.
Mycobacterial cultures were grown in Middlebrook 7H9 broth
medium or on Middlebrook agar 7H10 medium supplemented
with albumin-dextrose-catalase (ADC; Difco) and containing
0.05% Tween 80. The L-lysine monohydrochloride (Sigma) was
dissolved in distilled water and used at a concentration of 40 mg/
ml. For transformation, BCG cultures were grown to an optical
density at 600 nm of 0.9, transformed using a Bio-Rad gene pulser
electroporator at 2.5 kV, 25 mF, and 1,000 V, and plated onto
ADC-supplemented Middlebrook agar 7H10 medium containing
0.05% Tween 80. Commercial BCG Danish 1331 strain (Pfizer),
was kindly provided by Dr. Neus Altet and commercial BCG
Connaught strain (ImmuCyst, Aventis), from the Urology
Department at Hospital Clı́nic de Barcelona.
Dot-blot analysis
Cell lysates of mid-logarithmic-phase BCG transformants were
prepared by sonication and using a protein extraction buffer
(50 mM Tris-HCl pH 7.5, 5 mM EDTA, 0.6% sodium dodecyl
sulphate) and 1006 protease inhibitor cocktail (1 mg/ml aproti-
nin, 1 mg/ml E-64, 1 mg/ml leupeptin, 1 mg/ml pepstatin A,
50 mg/ml pefabloc SC, and 10 ml dimethyl sulfoxide). The
protein extract was blotted onto a pre-treated PVDF membrane,
and HIVA protein was detected using anti-Pk monoclonal
antibodies (MCA1360 AbD Serotec), with an ECL kit (Pierce).
To visualize the dots, the Typhoon 8600 gel imaging system (GE
Healthcare) was used.
In vivo stability of plasmid pJH222.HIVACAT
The growth of rBCG and the in vivo stability of the
extrachromosomal plasmid pJH222.HIVACAT were established
by the recovery of BCG.HIVACAT colonies from the spleens after
20 weeks after mice immunization with 105 cfu of BCG.HIVA-
CAT. Spleens were homogenized and plated onto Middlebrook
7H10 medium supplemented with ADC (Difco) and containing
0.05% Tween 80. The resulting colonies were inoculated in 7H9
medium supplemented with ADC and 0.05% Tween 80. The
DNA coding sequence corresponding to HIVA immunogen was
detected by PCR analysis, using the BCG liquid culture as a
template.
Sample preparation for the GenoType MTBC assay and
Multiplex PCR assay
For isolation of DNA from BCGwt, BCG.HIVA222, and
BCG.HIVACATstrains, 400 ml of mycobacterial culture were
centrifuged at 130006g for 10 minutes, at room temperature,
the pellet was resuspended in 250 ml of distilled water, and heated
to 95uC in a thermoblock for 15 minutes to lyse and inactivate
vegetative bacterial forms. Finally, after 5 minutes centrifugation
at 10,0006g, 5 ml of supernatant were used for the amplification
reaction or stored at 220uC. The commercial BCG strains were
treated in a similar way, but in this case, 400 ml of the
reconstituted freeze-dried flask were used.
GenoType MTBC assay for M. bovis BCG identification
The Mycobacterium bovis BCG strain identification was
performed with a commercially available system based on DNA
hybridization technology on nitrocellulose strips (GenoType
MTBC; Hain Diagnostika, Nehren, Germany). The GenoType
MTBC assay is based on an M. tuberculosis complex-specific 23S
ribosomal DNA fragment, gyrB DNA sequence polymorphisms,
and the RD1 deletion of M. bovis BCG. Specific oligonucleotides
targeting these polymorphisms are immobilized on membrane
strips. Amplicons derived from a multiplex PCR (performed using
the biotynilated primers provided with the kit) react with these
probes during hybridization. The Genotype MTBC assay was
performed as recommended by the manufacturer. Briefly, for
amplification, 35 ml of a primer nucleotide mixture (provided with
the kit), amplification buffer containing 2.5 mM MgCl2 and
1.25 U of HotStarTaq polymerase (Qiagen, Hilden, Germany),
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and 5 ml of DNA (see above sample preparation paragraph) in a
final volume of 50 ml were used. The amplification protocol
consisted of 15 min of denaturation at 95uC, followed by 10 cycles
comprising 30 s at 95uC and 120 s at 58uC, an additional 20
cycles comprising 25 s at 95uC, 40 s at 53uC, and 40 s at 70uC,
and a final extension at 70uC for 8 min [41]. Each biotin-labeled
PCR product was denatured and hybridized to a strip with 13
specific oligonucleotide probes, using a heat-controlled washing
and shaking automaton (GT-Blot 48; Hain Lifescience GmbH,
Nehren, Germany). The specificity and targeted genes (in
parentheses) of the probes were as follows: 1, conjugate
(hybridization) control; 2, Mycobacterium genus-specific amplifica-
tion control (23S rRNA); 3, M. tuberculosis complex-specific probe
for identification control (23S rRNA); 4 to 12, discriminative for
M. tuberculosis complex species (gyrB), and 13, M. bovis BCG specific
probe (RD1). Six different patterns could be obtained (M.
tuberculosis or M. canettii, M. africanum, M. bovis, M. bovis BCG, M.
caprae, and M. microti). A template sheet showing the positions of
the lines and the interpretation table, both provided with the kit,
were used for interpretation of the test results.
Multiplex PCR assay for M. bovis BCG Substrain Pasteur
Identification
The multiplex PCR was performed using 13 primers [38]
targeting the SenX3–RegX3 system (C3 and C5) and the BCG
deletion regions including RD1 (ET1-3), RD2, RD8, RD14 and
RD16 regions. For the PCR analysis, 5 ml of the DNA (see above
sample preparation paragraph) isolated from BCG.HIVACAT
Pasteur strain and BCG Danish 1331 strain was used in a final
volume of 50 ml with the following amplification protocol : 1 cycle
at 94uC (10 min) and 30 cycles at 94uC (1 min), 55uC (1 min) and
72uC (2 min), and 1 cycle at 72uC (10 min). The PCR products
were analyzed in a 3% (w/v) agarose gel electrophoresis. The PCR
fingerprints of BCG Pasteur and BCG Danish substrains were
consistent with previously published results on genetic information
of BCG substrains [38].
Mycobacterial plasmid DNA extraction
The rBCG broth culture up to an OD of 0.9 (600 nm) from
Master Seed and Working Stock, was used for mycobacterial
plasmid DNA isolation. The QIAprep Spin Miniprep Kit (Qiagen,
Hilden, Germany) was used with slight modifications :i) prior to
harvest (3 to 24 hours), glycine at a final concentration of 1% (w/
v) was added; ii) the cell pellet was treated with the P1 buffer from
the Miniprep Qiagen kit, supplemented with 10 mg/ml of
lysozyme (Sigma) and incubated at 37uC overnight; iii) the
extraction column was treated with a 10 ml mixture of
chloroform:isopropanol 1:1. The mycobacterial plasmid DNA
isolated was used for restriction enzyme analysis.
Mice immunizations and isolation of splenocytes
Adult (7-weeks-old) and newborn (7-days-old) female BALB/c
mice were immunized with BCG.HIVACAT, and were boosted
with MVA.HIVA or MVA.HIVA.85A at doses, routes and
schedules outlined in the figure legends. On the day of sacrifice,
individual spleens were collected and splenocytes were isolated by
pressing spleens through a cell strainer (Falcon) using a 5-ml
syringe rubber plunger. Following the removal of red blood cells
with ACK lysing buffer (Lonza), the splenocytes were washed and
resuspended in complete medium (R10 [RPMI 1640 supplement-
ed with 10% fetal calf serum and penicillin-streptomycin], 20 mM
HEPES, and 15 mM 2-mercaptoethanol).
Ethics statement
The animal experiments were approved by the local Research
Ethics Committee (Clinical Medicine, School of Medicine,
University of Barcelona and University of Oxford) and by the
Ethical Committee for animal experimentation from University of
Barcelona and University of Oxford. All animal procedures and
care conformed strictly to Catalonia (Spain) and to United
Kingdom Animal Welfare legislation.
Ex Vivo IFN-c ELISPOT Assay
The ELISPOT assay was performed using a commercial IFN-c
ELISPOT kit (Mabtech, Sweden). The ELISPOT plates (Milli-
pore, MSISP4510, 96 wells plates with PVDF membranes) were
coated with purified antimouse IFN-c capture monoclonal
antibody diluted in PBS to a final concentration of 5 mg/ml at
4uC overnight. The plates were washed once in R10 and blocked
for 2 h with R10. A total of 56105 fresh splenocytes were added to
each well, stimulated with 5 mg/ml of PPD for 16 h at 37uC, 5%
CO2, and lysed by incubating twice with deionized water for
5 minutes. Wells were then washed 36 with PBS 0.05% Tween
20, incubated for 2 h with a biotinylated anti-IFN-c mAb diluted
in PBS 2% FCS to a final concentration of 2 ug/ml, washed 36 in
PBS 0.05% Tween 20, and incubated with the Streptavidin-
Alkaline Phosphatase-conjugate in PBS 2% FCS. Wells were
washed 46with PBS 0.05% Tween 20 and 26with PBS before
incubating with 100 ml BCIP/NBT substrate solution (Sigma).
After 5–10 minutes, the plates were washed with tap water, dried,
and the resulting spots counted using an ELISPOT reader
(Autoimmune Diagnostika GmbH, Germany).
Intracellular Cytokine Staining
One million splenocytes were added to each well of a 96-well
round-bottomed plate (Costar) and pulsed with 2 mg/ml of P18-
I10 peptide (RGPGRAFVTI) [23] and kept at 37uC, 5% CO2 for
60 minutes, followed by the addition of GolgiStop (BD Bioscienc-
es) containing monensin. After a further 5-hour incubation,
reaction was terminated by storing the plate at 4uC. The cells
were washed with FACS wash buffer (PBS, 2% FCS, 0.01%
Azide) and blocked with anti-CD16/32 (BD Biosciences) at 4uC
for 30 minutes. All subsequent antibody stains were performed
using the same conditions. Cells were then washed and stained
with anti-CD8-PerCP (BD Biosciences) and anti CD107a-FITC,
washed again, and permeabilized using the Cytofix/Cytoperm kit
(BD Biosciences). Perm/Wash buffer (BD Biosciences) was used to
wash cells before staining with anti-IFN-c-APC, anti TNF-a-PE
and anti IL-2 Alexa Fluor 647 (BD Biosciences). Cells were fixed
with CellFIX (BD) and stored at 4uC until analysis.
Fluorescence-Activated Cell Sorter Analysis
All chromogen-labeled cells were analyzed in a Becton
Dickinson FACScalibur, using the CellQuest software for acqui-
sition (BD Biosciences) and the Flow-Jo software (Tri-Star) for
analysis.
Statistical analysis
Immunogenicity data are shown as group medians as well as
individual responses. The body mass data are group means, and
mean 6 2 SD in naı̈ve mice group. Statistical significance was
determined by ANOVA (* = p,0.05).
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